Advanced searches left 3/3

Catabolic - DOAJ

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Examining the effects of HMG-CoA reductase inhibitors on anabolic and catabolic signaling pathway proteins associated with degenerative disc disease

In addition, nucleus pulposus cells produced by statin-administered nucleus pulposus cells for the prevention of interleukin -1 beta-induced apoptosis and extracellular matrix degradation, according to kappa B. The primary aim of this review is to determine whether it is possible for pharmaceutical synthetic statin agents added to primary cell cultures isolated from human intervertebral disc tissue to stop and eliminate tissue degeneration by the anabolic/catabolic signaling pathways associated with inflammation. CONCLUSIONS: Other than IL-1-u03b2; NF-u03baB signaling pathway and SOX9; and SOX9. To help understand the regenerative effects of these two pharmacological agents on degenerated AF/NP cells, there is urgent need for prospective studies in which multiple signaling pathways and receptors on these pathways are investigated.

Source link: https://doaj.org/article/090c274034bc4e5a92aaa676c77c3027


Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes

Cancer cachexia is a multifactorial disorder characterized by a significant decrease in body mass attributed mainly to skeletal muscle and adipose tissue loss. For a long time, inflammatory factors have been the focus when designing drugs for the treatment of CC. A comprehensive understanding of how regulation of signal transmission leads to catabolic gene expression that underlies muscle wasting. In addition, we discuss epigenetic factors involved in muscle wasting's transcription of catabolic genes. We conclude with a few thoughts about the directions that may lead to new therapeutic approaches to treating CC.

Source link: https://doi.org/10.3390/cancers14174258


BDK inhibition acts as a catabolic switch to mimic fasting and improve metabolism in mice

Multiple diseases are linked to chain amino acid catabolic deficiencies, which are suspected to be causal mediators of multiple disorders. This research used BT2, a small molecule allosteric inhibitor of BDK in many mouse models of metabolic dysfunction and NAFLD, including the high fat diet model with acute and chronic treatment paradigms, the choline deficient, methionine minimal high fat diet model, and the low-density lipoprotein receptor null mouse model. To clarify liver-specific effects of BDK inhibition in HFD-fed mice, shRNA was also used to knock down BDK in liver. After BT2 therapy, HFD-fed and lean mice had a rapid rise in insulin sensitivity that was observed. In both instances, BT2 therapy reduced steatosis and/or inflammation. Mechanistically, BT2 therapy dramatically altered the expression of genes involved in liver fatty acid oxidation and lipogenesis, as well as upstream regulator results, suggesting that BT2 therapy enhanced PPARu03b1. However, BT2 did not respond to PPARu03b1 in vitro in vitro in vitro. In mice, shRNA-AAV-mediated knockdown of BDK specifically in liver in vivo did not have any effect on glycemia, steatosis, or PPAR-mediated gene expression, while mouse mice did not have any effect on mouse PPARu03b1-mediated gene expression. In several mouse models, these results show that BT2 therapy immediately improves metabolism and liver steatosis. While liver in BT2-treated mice show some molecular changes, these reactions were not present in mice with AAV-mediated shRNA knockdown of BDK. BCAA may provide a narcotic storage and reduced systemic BCAA levels as shown in this research by BDK inhibition, thus, this measure may continue to be a u201cfasting indicator.

Source link: https://doi.org/10.1016/j.molmet.2022.101611


A novel prognostic model for prostate cancer based on androgen biosynthetic and catabolic pathways

Androgen deprivation therapy reduces tumor formation by limiting androgen levels, either surgically or pharmacologically. However, patients treated with ADT nevertheless experience biochemical recurrence and progress to castration-resistant prostate cancer, which has been attributed to androgen biosynthetic and catabolic pathways. Hence, gene expression profiles and medical data of PCa patients based on androgen biosynthetic and catabolic pathways were obtained from TCGA, MSKCC, and GEO databases for consensus clustering based on androgen biosynthetic and catabolic pathways. Patients were divided into two groups based on their risk profiles: high risk and low risk, and survival analysis was used to determine the difference between the two groups in biochemical recurrence-free time. These results show that the prognostic model can be used as a predicting device to guide clinical therapy and provide new insight into prostate cancer basic research.

Source link: https://doi.org/10.3389/fonc.2022.950094


Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay

The Ortho Hydroxy-Protected Aryl Sulfate linker, which comes in the form of a newly developed linker in the form of a di-aryl sulfate linker with phenolic payload and a self-immolating group. The OHPAS linker was stable in mouse and human plasma, as well as in mouse pharmacokinetic experiments, as shown by in vivo and in vivo, whereas mouse VC-PABC linker was very variable in mice in vitro and in vivo, as a result. In conclusion, the OHPAS linker appears to be a good linker for ADC, and further experiments may be required to demonstrate the effectiveness and toxicity of the OHPAS linker.

Source link: https://doi.org/10.3390/pharmaceutics13010125


Silymarin modulates catabolic cytokine expression through Sirt1 and SOX9 in human articular chondrocytes

In a chondrocyte cell line treated with SMN, there was chondroprotection against tumour necrosis factor-alpha stimulation. However, pre- and post-treatment with phytochemicals have differing effects on osteoarthritis chondrocytes, and the therapeutic potential of SMN following catabolic cytokine stimulation is not fully understood. Methods The cytotoxicity of SMN was determined in human primary chondrocytes. Cell Death In IL-1u03b2-stimulated cells, high-dose SMN reduced mitochondrial function in chondrocytes, and 50 bcM SMN increased cell death. In addition, TIMP-1's production of IL-1, MMP-3, and MMP-9 decreased as a result of an increase in TIMP-1 secretion. SMN's chondrocyte phenotype is controlled by Sirt1 and SOX9 to increase ECM homeostasis and possibly serve as a complementary therapy for early-stage knee osteopathy.

Source link: https://doi.org/10.1186/s13018-021-02305-9


4-Methylumbelliferone suppresses catabolic activation in anterior cruciate ligament-derived cells via a mechanism independent of hyaluronan inhibition

Abstract Background The anterior cruciate ligament plays a vital role as a dynamic stabilizer of the knee joints, and osteoarthritis progression accelerates osteoarthritis progression. Methods We investigated whether 4-MU affects the expression of catabolic enzymes, such as matrix metalloproteinase -1, MMP-3, and interleukin -6, among ACL-derived cells and ACL explant cultures using immunohistochemistry, real-time RT-qPCR, and capillary western immunoassay in ACL-derived cells and ACL explant cultures using immunohistochemistry, real-time RT-qPCR, and ACL he In ACL-derived cells, we found that 4-MU suppressed the IL-u03b2-induced rise in pro-catabolic factors such as MMP-1, MMP-3, and IL-6 for the first time. In IL-1u03b2-activated ACL-derived cells, a reduced reliance on glycolysis was also reversed. Conclusions 4U4 may be a safe and beneficial treatment for knee osteoarthritis as a result of its anti-inflammatory action on not only chondrocytes but also on ligament cells.

Source link: https://doi.org/10.1186/s13018-021-02637-6


The catabolic-to-anabolic shift seen in the canine osteoarthritic cartilage treated with knee joint distraction occurs after the distraction period

Animal experiments that are representative of the human osteoarthritic disease epidemic and research the effects of KJD at two time points may be helpful in this regard but are lacking. On two timepoints, this report investigated the effects of KJD on the osteoarthritic joint of dogs. After ten weeks of follow-up after KJD treatment, the cartilage, subchondral bone, and synovial membrane were investigated closely after KJD therapy, and after ten weeks of follow-up. Results: Immediately after KJD proteoglycan and collagen type II samples were reduced, proteoglycan and collagen type II contents were reduced, proteoglycan production was reduced, proteoglycan synthesis was restored. After ten weeks of sequel-up, proteoglycan and collagen type II samples were partially restored, and proteoglycan synthesis was enhanced. Translational Potential of this Article: Further clarification of the regenerative mechanisms behind KJD may be able to enhance the existing KJD treatment.

Source link: https://doi.org/10.1016/j.jot.2022.09.003

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions